Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: JJINV who wrote (1210)	10/26/2025 3:10:46 PM
From: bobbseytwins2001	4 Recommendations Recommended By Davidoff erippetoe Fitzhughlaw JJINV Respond to of 1216

Wall Street has never been a bastion of honesty and truth, but usually it offers at least an attempt to provide some knowledge when it comes to investing. But we all know what happens when people like Feurstein crawl out from under a rock. Here we have a poly sci major in college routinely claiming he understands biology better than most of the brightest minds in medicine. His op-ed on Anktiva is a prime example of misleading people by using journalism rather than knowledge to slant an article with a couple of "factoids" to attempt to create doubts in investors minds, while dismissing years of comprehensive data and study. We all know how effective he has been at destroying scientist's hopes and dreams by helping to sink their fledgling companies and products over too many years. It is a sad commentary. But, we will continue to take the word of genius billionaire PSS over Feurstein when we make investments every single time, win or lose.

To: JJINV who wrote (1210)	10/26/2025 3:11:39 PM
From: waitwatchwander	3 Recommendations Recommended By Fitzhughlaw JJINV Stanley Lake 92 Read Replies (2) \| Respond to of 1216

He makes some good points as to the study. His critique as to credibility of survivability is based upon similar reasoning. PSS has been dealing with later stage cancer patients for much of his medical career. I'm sure he does have a good anecdotal take on the value of Anktiva. Concerns About Study Design - No control group or comparator arm. - Lymphocyte count thresholds were defined retrospectively, introducing bias. - The frequency and consistency of lymphocyte measurements were unclear. Feuerstein suggests these flaws undermine the credibility of the survival benefit claims.